Amarin Corp Plcuk AMRN
NASDAQ AMRN
$14.09 +0.03 (+0.21%)
At close: Aug 21, 2026 · 4:00 PM EDT

Amarin Corp Plcuk (AMRN) Total Non-Current Liabilities (2010 - 2026)

Amarin Corp Plc\Uk (AMRN) posted quarterly Total Non-Current Liabilities of $169.4 million for Q2 2026, down 12.33% year-over-year from $193.3 million in Q2 2025, and down 8.52% quarter-over-quarter from $185.2 million in Q1 2026.

Amarin Corp Plcuk (AMRN) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends

Amarin Corp Plc\Uk (AMRN) has reported Total Non-Current Liabilities for 17 consecutive years, with $169.4 million the latest figure, recorded in Q2 2026.

  • In Q2 2026, Total Non-Current Liabilities fell 12.33% year-over-year to $169.4 million; the TTM figure through Jun 2026 stood at $169.4 million (down 12.33% YoY), while the FY2025 annual figure was $200.5 million, up 6.86% from the prior year.
  • Total Non-Current Liabilities fell to $169.4 million in Q2 2026 per AMRN's latest filing, from $185.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $385.6 million in Q2 2022 and bottomed at $169.4 million in Q2 2026.
  • Historically, Total Non-Current Liabilities has averaged $243.5 million across 5 years, with a median of $236.8 million in 2024.
  • Annual changes were most pronounced in 2024 — Total Non-Current Liabilities plunged 30.63% — and 2026, when it gained 8.74%.
  • Amarin Corp Plc\Uk's Total Non-Current Liabilities stood at $282.6 million in 2022, then decreased by 4.29% to $270.5 million in 2023, then slumped by 30.63% to $187.7 million in 2024, then grew by 6.86% to $200.5 million in 2025, then slipped by 15.5% to $169.4 million in 2026.
  • Business Quant data shows AMRN's Total Non-Current Liabilities at $169.4 million in Q2 2026, $185.2 million in Q1 2026, and $200.5 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn 105.99 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn 100.51 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn 122.23 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn 48.34 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn 33.91 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn 92.80 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn 47.87 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn 100.86 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn -30.89 Bn
10 Amarin Corp Plcuk 5.86 Bn 5.54 Bn 14.99 Mn 169.45 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 169.45 Mn
Mar 31, 2026 185.23 Mn
Dec 31, 2025 200.54 Mn
Sep 30, 2025 188.96 Mn
Jun 30, 2025 193.28 Mn
Mar 31, 2025 170.35 Mn
Dec 31, 2024 187.67 Mn
Sep 30, 2024 209.77 Mn
Jun 30, 2024 238.64 Mn
Mar 31, 2024 234.88 Mn
Dec 31, 2023 270.52 Mn
Sep 30, 2023 278.61 Mn
Jun 30, 2023 283.74 Mn
Mar 31, 2023 266.79 Mn
Dec 31, 2022 282.64 Mn
Sep 30, 2022 310.78 Mn
Jun 30, 2022 385.56 Mn
Mar 31, 2022 325.11 Mn
Dec 31, 2021 393.32 Mn
Sep 30, 2021 387.96 Mn